Kite gives it­self a lit­tle more time to fin­ish FDA ap­pli­ca­tion for KTE-C19

Kite Phar­ma has giv­en it­self un­til Q1 2017 to com­plete the BLA fil­ing for KTE-C19, its pi­o­neer­ing en­gi­neered T-cell ther­a­py. That’s a slight push­back of the orig­i­nal sched­ule out­lined by CEO Arie Bellde­grun, who last month set a goal to fin­ish the sub­mis­sion by the end of 2016.

Ea­ger to ce­ment first-mover in CAR-T, Bellde­grun was ready to go with pos­i­tive three-month re­sults for the ther­a­py in ad­vanced dif­fuse large B-cell lym­phoma (DL­B­CL). Now the com­pa­ny says it’ll be­gin the BLA sub­mis­sion by the end of De­cem­ber, which will give it time to sub­mit 6-month da­ta from its ZU­MA-1 piv­otal tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER